Report Information More information from: https ://www.wis eguyreports .com/reports /575867
Potassium Voltage Gated Channel Subfamily A Member 3 (Voltage Gated Potassium Channel Subunit Kv1.3 or KCNA3) - Pipeline Review, H1 2016 Report / Search Code: WGR575867
Price
1-user P DF : $ 3500.0
Description:
Publish Date: 28 June, 2016
Site P DF : $ 7000.0
Enterprise P DF : $ 10500.0
Potas s ium Voltage Gated Channel Subfamily A Member 3 (Voltage Gated Potas s ium Channel Subunit Kv1.3 or KCNA3) - Pipeline Review, H1 2016 Summary Global Markets Direct’s , ‘Potas s ium Voltage Gated Channel Subfamily A Member 3 (Voltage Gated Potas s ium Channel Subunit Kv1.3 or KCNA3) - Pipeline Review, H1 2016’, provides in depth analys is on Potas s ium Voltage Gated Channel Subfamily A Member 3 (Voltage Gated Potas s ium Channel Subunit Kv1.3 or KCNA3) targeted pipeline therapeutics . The report provides comprehens ive information on the Potas s ium Voltage Gated Channel Subfamily A Member 3 (Voltage Gated Potas s ium Channel Subunit Kv1.3 or KCNA3), targeted therapeutics , complete with analys is by indications , s tage of development, mechanis m of action (MoA), route of adminis tration (RoA) and molecule type. The report als o covers the des criptive pharmacological action of the therapeutics , its complete res earch and development his tory and lates t news and pres s releas es . Additionally, the report provides an overview of key players involved in Potas s ium Voltage Gated Channel Subfamily A Member 3 (Voltage Gated Potas s ium Channel Subunit Kv1.3 or KCNA3) targeted therapeutics development and features dormant and dis continued projects . Global Markets Direct’s report features inves tigational drugs from acros s globe covering over 20 therapy areas and nearly 3,000 indications . The report is built us ing data and information s ourced from Global Markets Direct’s proprietary databas es , company/univers ity webs ites , clinical trial regis tries , conferences , SEC filings , inves tor pres entations and featured pres s releas es from company/univers ity s ites and indus try-s pecific third party s ources . Drug profiles featured in the report undergoes periodic review following a s tringent s et of proces s es to ens ure that all the profiles are updated with the lates t s et of information. Additionally, various dynamic tracking proces s es ens ure that the mos t recent developments are captured on a real time bas is . The report helps in identifying and tracking emerging players in the market and their portfolios , enhances decis ion making capabilities and helps to create effective counter s trategies to gain competitive advantage. Note*: Certain s ections in the report may be removed or altered bas ed on the availability and relevance of data. Scope - The report provides a s naps hot of the global therapeutic lands cape for Potas s ium Voltage Gated Channel Subfamily A Member 3 (Voltage Gated Potas s ium Channel Subunit Kv1.3 or KCNA3) - The report reviews Potas s ium Voltage Gated Channel Subfamily A Member 3 (Voltage Gated Potas s ium Channel Subunit Kv1.3 or KCNA3) targeted therapeutics under development by companies and univers ities /res earch ins titutes bas ed on information derived from company and indus try-s pecific s ources - The report covers pipeline products bas ed on various s tages of development ranging from pre-regis tration till dis covery and undis clos ed s tages - The report features des criptive drug profiles for the pipeline products which includes , product des cription, des criptive MoA, R& D brief, licens ing and collaboration details & other developmental activities - The report reviews key players involved in Potas s ium Voltage Gated Channel Subfamily A Member 3 (Voltage Gated Potas s ium Channel Subunit Kv1.3 or KCNA3) targeted therapeutics and enlis ts all their major and minor projects - The report as s es s es Potas s ium Voltage Gated Channel Subfamily A Member 3 (Voltage Gated Potas s ium Channel Subunit Kv1.3 or KCNA3) targeted therapeutics bas ed on mechanis m of action (MoA), route of adminis tration (RoA) and molecule type
- The report s ummarizes all the dormant and dis continued pipeline projects - The report reviews lates t news and deals related to Potas s ium Voltage Gated Channel Subfamily A Member 3 (Voltage Gated Potas s ium Channel Subunit Kv1.3 or KCNA3) targeted therapeutics Reas ons to buy - Gain s trategically s ignificant competitor information, analys is , and ins ights to formulate effective R& D s trategies - Identify emerging players with potentially s trong product portfolio and create effective counter-s trategies to gain competitive advantage - Identify and unders tand the targeted therapy areas and indications for Potas s ium Voltage Gated Channel Subfamily A Member 3 (Voltage Gated Potas s ium Channel Subunit Kv1.3 or KCNA3) - Identify the us e of drugs for target identification and drug repurpos ing - Identify potential new clients or partners in the target demographic - Develop s trategic initiatives by unders tanding the focus areas of leading companies - Plan mergers and acquis itions effectively by identifying key players and it’s mos t promis ing pipeline therapeutics - Devis e corrective meas ures for pipeline projects by unders tanding Potas s ium Voltage Gated Channel Subfamily A Member 3 (Voltage Gated Potas s ium Channel Subunit Kv1.3 or KCNA3) development lands cape - Develop and des ign in-licens ing and out-licens ing s trategies by identifying pros pective partners with the mos t attractive projects to enhance and expand bus ines s potential and s cope Contents:
Table of Contents Table of Contents 2 Lis t of Tables 5 Lis t of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Potas s ium Voltage Gated Channel Subfamily A Member 3 (Voltage Gated Potas s ium Channel Subunit Kv1.3 or KCNA3) Overview 7 Therapeutics Development 8 Potas s ium Voltage Gated Channel Subfamily A Member 3 (Voltage Gated Potas s ium Channel Subunit Kv1.3 or KCNA3) - Products under Development by Stage of Development 8 Potas s ium Voltage Gated Channel Subfamily A Member 3 (Voltage Gated Potas s ium Channel Subunit Kv1.3 or KCNA3) - Products under Development by Therapy Area 9 Potas s ium Voltage Gated Channel Subfamily A Member 3 (Voltage Gated Potas s ium Channel Subunit Kv1.3 or KCNA3) - Products under Development by Indication 10 Potas s ium Voltage Gated Channel Subfamily A Member 3 (Voltage Gated Potas s ium Channel Subunit Kv1.3 or KCNA3) - Pipeline Products Glance 12 Early Stage Products 12 Potas s ium Voltage Gated Channel Subfamily A Member 3 (Voltage Gated Potas s ium Channel Subunit Kv1.3 or KCNA3) - Products under Development by Companies 13 Potas s ium Voltage Gated Channel Subfamily A Member 3 (Voltage Gated Potas s ium Channel Subunit Kv1.3 or KCNA3) - Products under Development by Univers ities /Ins titutes 16 Potas s ium Voltage Gated Channel Subfamily A Member 3 (Voltage Gated Potas s ium Channel Subunit Kv1.3 or KCNA3) - Therapeutics As s es s ment 18 As s es s ment by Monotherapy/Combination Products 18 As s es s ment by Mechanis m of Action 19 As s es s ment by Route of Adminis tration 20 As s es s ment by Molecule Type 22 Potas s ium Voltage Gated Channel Subfamily A Member 3 (Voltage Gated Potas s ium Channel Subunit Kv1.3 or KCNA3) - Companies Involved in Therapeutics Development 24 Amgen Inc. 24 Axxam SpA 25 Bionomics Limited 26 conoGenetix bios ciences GmbH 27 Johns on & Johns on 28 Kineta, Inc. 29 Sevion Therapeutics , Inc. 30 Potas s ium Voltage Gated Channel Subfamily A Member 3 (Voltage Gated Potas s ium Channel Subunit Kv1.3 or KCNA3) - Drug Profiles 31 BNC-164 - Drug Profile 31 Product Des cription 31 Mechanis m Of Action 31 R& D Progres s 31 cgtx-A - Drug Profile 32 Product Des cription 32 Mechanis m Of Action 32 R& D Progres s 32 cgtx-F - Drug Profile 33 Product Des cription 33
Mechanis m Of Action 33 R& D Progres s 33 cgtx-G - Drug Profile 34 Product Des cription 34 Mechanis m Of Action 34 R& D Progres s 34 dalazatide - Drug Profile 35 Product Des cription 35 Mechanis m Of Action 35 R& D Progres s 35 KPI-150 - Drug Profile 40 Product Des cription 40 Mechanis m Of Action 40 R& D Progres s 40 KPI-190 - Drug Profile 41 Product Des cription 41 Mechanis m Of Action 41 R& D Progres s 41 OSK-1 - Drug Profile 42 Product Des cription 42 Mechanis m Of Action 42 R& D Progres s 42 Recombinant Peptide to Block Kv1.3 Ion Channel for Autoimmune Dis eas es - Drug Profile 43 Product Des cription 43 Mechanis m Of Action 43 R& D Progres s 43 Recombinant Peptides to Block Kv1.3 Channel for Autoimmune Dis eas es - Drug Profile 44 Product Des cription 44 Mechanis m Of Action 44 R& D Progres s 44 Small Molecules to Block Kv1.3 Ion Channel for Multiple Scleros is , Immunology, Inflammatory Bowel Dis eas e and Type 1 Diabetes - Drug Profile 45 Product Des cription 45 Mechanis m Of Action 45 R& D Progres s 45 SVN-001 - Drug Profile 46 Product Des cription 46 Mechanis m Of Action 46 R& D Progres s 46 Synthetic Peptides to Block Potas s ium Voltage-Gated Channel Subfamily A Member 3 (Kv1.3) for Autoimmune Dis orders - Drug Profile 47 Product Des cription 47 Mechanis m Of Action 47 R& D Progres s 47 Potas s ium Voltage Gated Channel Subfamily A Member 3 (Voltage Gated Potas s ium Channel Subunit Kv1.3 or KCNA3) - Dormant Projects 48 Potas s ium Voltage Gated Channel Subfamily A Member 3 (Voltage Gated Potas s ium Channel Subunit Kv1.3 or KCNA3) - Featured News & Pres s Releas es 50 Jun 10, 2016: Alliance for Children Therapeutics Pres ents Dalazatide Data Demons trating Pos itive Res pons e in Lupus 50 May 23, 2016: KPI Therapeutics to Pres ent Updated Dalazatide Study Data in Lupus 51 May 12, 2016: KPI Therapeutics Pres ents Dalazatide Plaque Ps orias is Data at Dermatology Conference 51 Feb 08, 2016: KPI Therapeutics Initiates Res earch Program In Skin Dis eas es 51 Feb 08, 2016: KPI Therapeutics Initiates Res earch Program In Eye Dis eas es 52 Nov 10, 2015: Kineta, Seattle Children’s Res earch Ins titute Pres ent New Data Demons trating Pos itive, Predictive Res pons es to Dalazatide In Lupus 52 Nov 09, 2015: Kineta Pres ents New Data Demons trating Pos itive, Predictive Res pons es to Dalazatide in Ps orias is Patients and in Lupus , ANCA Vas culitis Studies at American College of Rheumatology Annual Meeting 53 Aug 08, 2015: Kineta Pres ents Updated Data on Dalazatide Clinical Trial at 12th World Congres s on Inflammation 54 Jun 17, 2015: ACT Res earch Sugges ts Role for Dalazatide in Blocking T Cells from Patients with Lupus 54 Jun 09, 2015: Kineta To Give Update On Dalazatide Clinical Trial Res ults At BIO International Meeting 55 Jun 05, 2015: Sevion Therapeutics to Pres ent at International Antibody Meeting 55 May 05, 2015: Kineta Announces Promis ing Top-line Clinical Res ults for Dalazatide; Target Implicated in Broad Array of Autoimmune Dis eas es 56 May 04, 2015: Sevion Therapeutics Pres ents Cow Antibody Platform at PEGS 2015 57 Apr 21, 2015: Kineta, Univers ity of Groningen Pres ent New, Pos itive Data for Dalazatide in ANCA Vas culitis , an Orphan Dis eas e 58 Mar 19, 2015: Kineta’s ShK-186 Shows Encouraging Early Res ults as Potential Therapy for Autoimmune Eye Dis eas es 58
Appendix 60 Methodology 60 Coverage 60 Secondary Res earch 60 Primary Res earch 60 Expert Panel Validation 60 Contact Us 60 Dis claimer 61 Lis t of Tables Number of Products under Development for, H1 2016 8 Number of Products under Development by Therapy Area, H1 2016 9 Number of Products under Development by Indication, H1 2016 10 Comparative Analys is by Early Stage Products , H1 2016 12 Number of Products under Development by Companies , H1 2016 13 Products under Development by Companies , H1 2016 14 Products under Development by Companies , H1 2016 (Contd..1) 15 Number of Products under Inves tigation by Univers ities /Ins titutes , H1 2016 16 Products under Inves tigation by Univers ities /Ins titutes , H1 2016 17 As s es s ment by Monotherapy/Combination Products , H1 2016 18 Number of Products by Stage and Mechanis m of Action, H1 2016 19 Number of Products by Stage and Route of Adminis tration, H1 2016 21 Number of Products by Stage and Molecule Type, H1 2016 23 Pipeline by Amgen Inc., H1 2016 24 Pipeline by Axxam SpA, H1 2016 25 Pipeline by Bionomics Limited, H1 2016 26 Pipeline by conoGenetix bios ciences GmbH, H1 2016 27 Pipeline by Johns on & Johns on, H1 2016 28 Pipeline by Kineta, Inc., H1 2016 29 Pipeline by Sevion Therapeutics , Inc., H1 2016 30 Dormant Projects , H1 2016 48 Dormant Projects (Contd..1), H1 2016 49 Lis t of Figures Number of Products under Development for, H1 2016 8 Number of Products under Development by Therapy Area, H1 2016 9 Number of Products under Development by Top 10 Indication, H1 2016 10 Comparative Analys is by Early Stage Products , H1 2016 12 As s es s ment by Monotherapy/Combination Products , H1 2016 18 Number of Products by Stage and Mechanis m of Actions , H1 2016 19 Number of Products by Routes of Adminis tration, H1 2016 20 Number of Products by Stage and Routes of Adminis tration, H1 2016 20 Number of Products by Molecule Types , H1 2016 22 Number of Products by Stage and Molecule Type, H1 2016 22
wis eguyreports .com / Phone (US) + 1-646-845-9349 (UK) +44 208 133 9349